tragacanth supplementation and type 2 diabetes

The effect of tragacanth supplementation on the status of metabolic, inflammatory parameters and mental health in women with type 2 diabetes

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150205020965N6

Enrollment

Registered

2020-10-30

Start date

2020-11-21

Completion date

Unknown

Last updated

2020-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes. Type 2 Diabetes mellitus

Interventions

Intervention 1: Intervention group: tragacanth gum. This group will dissolve and consume two sachets (2* 5 gr) of tragacanth gum ( Payar Tejarat Zomorodin Company, Iran) twice a day, in the morning

Eligibility

Sex/Gender

Female

Age

30 Years to 50 Years

Inclusion criteria

Inclusion criteria: Having type 2 diabetes for more than six months according to International Diabetes Federation (fasting blood sugar level more than 126 mg/dl) age: 30-50 y Using anti-diabetic drugs and maintaining them in the period of the study Having a normal diet Body Mass Index (BMI) more than 25 kg/m2 in the last 3 months

Exclusion criteria

Exclusion criteria: Having a history of gastrointestinal Having history cardiovascular Having a history of renal Having a history of thyroid Having a history of liver; or pancreatic diseases Pregnancy and lactating Smokers Consuming prebiotic and probiotics’ products Consuming antibiotics; antiacids; alcohol; anti-diarrheal; anti-inflammatory; lipid-lowering; laxatives or insulin Having a typical fiber intake of more than 30g/d.

Design outcomes

Primary

Measure	Time frame
HbA1c. Timepoint: At baseline and two months after baseline. Method of measurement: kit.;Lipid profile (TG, TC, HDL-c). Timepoint: At baseline and three two after baseline. Method of measurement: Hitachi 911 auto-analyzer.;Tryptophan. Timepoint: At baseline and two months after baseline. Method of measurement: kit.;Kynurenine. Timepoint: At baseline and two months after baseline. Method of measurement: kit.;Fasting glucose. Timepoint: En At baseline and two months after baseline. Method of measurement: Hitachi 911 auto-analyzer.;Cortisol. Timepoint: At baseline and two months after baseline. Method of measurement: kit.;Glucagon-like peptide1. Timepoint: At baseline and two months after baseline. Method of measurement: kit.;Fasting insulin. Timepoint: At baseline and three months after baseline. Method of measurement: Chemoluminescense.;Carboxymethyl lysine. Timepoint: At baseline and two months after baseline. Method of measurement: kit.;S-RAGE (soluble receptor for AGE). Timepoint: At baseline and two months after baseline. Method of measurement: kit.;Nitric oxide. Timepoint: At baseline and two months after baseline. Method of measurement: kit.;Interleukin 6. Timepoint: At baseline and two months after baseline. Method of measurement: kit.;Highly sensitive C-reactive protein(hs-CRP ). Timepoint: At baseline and two months after baseline. Method of measurement: ELISA Dedicated Kit.;Tumor Necrosis Factor(TNF). Timepoint: At baseline and two months after baseline. Method of measurement: ELISA Dedicated Kit.;Interleukin 10(IL10 ). Timepoint: At baseline and two months after baseline. Method of measurement: ELISA Dedicated Kit.;Total antioxidant capacity. Timepoint: At baseline and two months after baseline. Method of measurement: kit.;Malondialdehyde. Timepoint: At baseline and two months after baseline. Method of measurement: kit.;8-iso-prostaglandin F2a (8-iso-PGF2a). Timepoint: At baseline and two months after baseline. Method of measurement: kit.;Leptin. Tim	—

Measure

Time frame

HbA1c. Timepoint: At baseline and two months after baseline. Method of measurement: kit.;Lipid profile (TG, TC, HDL-c). Timepoint: At baseline and three two after baseline. Method of measurement: Hitachi 911 auto-analyzer.;Tryptophan. Timepoint: At baseline and two months after baseline. Method of measurement: kit.;Kynurenine. Timepoint: At baseline and two months after baseline. Method of measurement: kit.;Fasting glucose. Timepoint: En At baseline and two months after baseline. Method of measurement: Hitachi 911 auto-analyzer.;Cortisol. Timepoint: At baseline and two months after baseline. Method of measurement: kit.;Glucagon-like peptide1. Timepoint: At baseline and two months after baseline. Method of measurement: kit.;Fasting insulin. Timepoint: At baseline and three months after baseline. Method of measurement: Chemoluminescense.;Carboxymethyl lysine. Timepoint: At baseline and two months after baseline. Method of measurement: kit.;S-RAGE (soluble receptor for AGE). Timepoint: At baseline and two months after baseline. Method of measurement: kit.;Nitric oxide. Timepoint: At baseline and two months after baseline. Method of measurement: kit.;Interleukin 6. Timepoint: At baseline and two months after baseline. Method of measurement: kit.;Highly sensitive C-reactive protein(hs-CRP ). Timepoint: At baseline and two months after baseline. Method of measurement: ELISA Dedicated Kit.;Tumor Necrosis Factor(TNF). Timepoint: At baseline and two months after baseline. Method of measurement: ELISA Dedicated Kit.;Interleukin 10(IL10 ). Timepoint: At baseline and two months after baseline. Method of measurement: ELISA Dedicated Kit.;Total antioxidant capacity. Timepoint: At baseline and two months after baseline. Method of measurement: kit.;Malondialdehyde. Timepoint: At baseline and two months after baseline. Method of measurement: kit.;8-iso-prostaglandin F2a (8-iso-PGF2a). Timepoint: At baseline and two months after baseline. Method of measurement: kit.;Leptin. Tim

—

Secondary

Measure	Time frame
Body Mass Index (BMI). Timepoint: At baseline and three months after baseline. Method of measurement: Scale-Meter.;Amount of received energy. Timepoint: At baseline and three months after baseline. Method of measurement: questionnaire.;Daily macronutrient intake (carbohydrate, protein, fat). Timepoint: At baseline and three months after baseline. Method of measurement: questionnaire.;Waist circumference (WHR). Timepoint: At baseline and three months after baseline. Method of measurement: Calculate by splitting waist to hip.;Blood pressure. Timepoint: At baseline and three months after baseline. Method of measurement: Mercuric barometr.;Assessment of the body composition. Timepoint: At baseline and three months after baseline. Method of measurement: BIA devices.;Mental health. Timepoint: At baseline and two months after baseline. Method of measurement: questionnaire.;Appetite status. Timepoint: At baseline and two months after baseline. Method of measurement: questionnaire.;Food intake. Timepoint: At baseline and two months after baseline. Method of measurement: questionnaire.	—

Measure

Time frame

Body Mass Index (BMI). Timepoint: At baseline and three months after baseline. Method of measurement: Scale-Meter.;Amount of received energy. Timepoint: At baseline and three months after baseline. Method of measurement: questionnaire.;Daily macronutrient intake (carbohydrate, protein, fat). Timepoint: At baseline and three months after baseline. Method of measurement: questionnaire.;Waist circumference (WHR). Timepoint: At baseline and three months after baseline. Method of measurement: Calculate by splitting waist to hip.;Blood pressure. Timepoint: At baseline and three months after baseline. Method of measurement: Mercuric barometr.;Assessment of the body composition. Timepoint: At baseline and three months after baseline. Method of measurement: BIA devices.;Mental health. Timepoint: At baseline and two months after baseline. Method of measurement: questionnaire.;Appetite status. Timepoint: At baseline and two months after baseline. Method of measurement: questionnaire.;Food intake. Timepoint: At baseline and two months after baseline. Method of measurement: questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactParvin Dehghan

Tabriz University of Medical Sciences

dehghan.nut@gmail.com+98 33340634

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026